EXECUTIVE INSIGHTS
DOMAIN EXPERTS
PLAYERS
PARTICIPANTS
-
JUL 2024
-
EDITION 21
-
TABLES 306
-
REGIONS 30
-
SEGMENTS 10
-
PAGES 578
-
US$ 5450
-
MCP-5064
-
JOIN OUR PANEL
EXECUTIVE ENGAGEMENTS BY TIER
-
CXO
-
VICE PRESIDENT
-
DIRECTOR
-
MANAGER
-
MARKETING
© Copy rights Global Industry Analysts, Inc., USA. www.strategyr.com All Rights Reserved.
OUR EXPERT PANELS
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
WHY PARTICIPATE?
Expertise to the Power of YOU!
- Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
- Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
- Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
- Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
- Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription
- The Economist
- MIT Technology Review
- Harvard Business Review
Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.
MARKETGLASS
BASIC
- Annual Prepaid Subscription
- Single-User
- 10,000 Data Room Credits/Month
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use MarketGlassTM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
PREMIUM
- Annual Prepaid Subscription
- One Research Project With One Complimentary Update/Year
- 10-User License
- 10-User Peer-to-Peer Collaborative Features
- 200 Domain Expert Insights (With Name, Company, and Date)
- 50,000 Data Room Credits
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
- Use Your Own Data and MarketGlassTM Data Room Content.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
- Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges
ENTERPRISE
- Annual Prepaid Subscription
- Four Research Projects With One Complimentary Update/Year
- 25-User License
- 25-User Peer-to-Peer Collaborative Engagements
- 500 Domain Expert Insights (With Name, Company, and Date)
- 150,000 Data Room Credits
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
- Use Your Own Data and MarketGlassTM Data Room Content.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
- Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges
HIGHLIGHTS & REPORT INDEX
Global Analgesics Market to Reach US$72.8 Billion by 2030
The global market for Analgesics estimated at US$51.1 Billion in the year 2023, is expected to reach US$72.8 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2023-2030. Prescription, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$43.8 Billion by the end of the analysis period. Growth in the OTC segment is estimated at 5.7% CAGR over the analysis period.
The U.S. Market is Estimated at US$16.5 Billion While China is Forecast to Grow at 7.0% CAGR
The Analgesics market in the U.S. is estimated at US$16.5 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.8 Billion by the year 2030 trailing a CAGR of 7.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.
Global Analgesics Market - Key Trends & Drivers Summarized
Analgesics, commonly known as painkillers, are a diverse group of drugs used to relieve pain. They work by blocking pain signals in the brain or by interfering with the brain`s interpretation of these signals. There are several types of analgesics, each suited to different types and severities of pain. The most well-known categories include nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin, which reduce inflammation and are effective for mild to moderate pain. Opioids like morphine and oxycodone are stronger analgesics, often prescribed for severe pain but come with a risk of dependency and addiction. Another category is acetaminophen (paracetamol), which is widely used for mild to moderate pain relief and fever reduction, often included in over-the-counter medications.
The use of analgesics has evolved significantly over the years, driven by advances in medical research and an increasing understanding of pain mechanisms. New formulations and delivery methods, such as extended-release tablets and transdermal patches, have improved the efficacy and convenience of pain management. Additionally, the development of combination drugs that incorporate multiple analgesics into a single dose has enhanced pain relief outcomes by targeting different pain pathways simultaneously. However, the widespread use of analgesics, particularly opioids, has led to significant public health challenges, including the opioid crisis, characterized by high rates of addiction and overdose. This has prompted a shift towards finding safer, non-addictive pain relief options, such as the development of new NSAIDs with fewer gastrointestinal side effects and increased research into non-pharmacological therapies.
The growth in the analgesics market is driven by several factors. Advancements in drug delivery systems have made analgesics more effective and user-friendly, with innovations like patient-controlled analgesia pumps and wearable drug delivery devices gaining popularity. The rising prevalence of chronic diseases such as arthritis and cancer, which often require long-term pain management, has also fueled demand for analgesics. Additionally, an aging global population is contributing to increased consumption of these medications, as older adults are more likely to experience chronic pain conditions. Consumer behavior trends show a growing preference for over-the-counter analgesics for quick and accessible pain relief, further boosting market growth. Moreover, increased healthcare spending and greater access to medical care in developing regions are expanding the market`s reach. Pharmaceutical companies are also investing heavily in research and development to create new analgesics with better safety profiles and effectiveness, responding to the growing demand for safer alternatives to traditional painkillers. These factors collectively underscore the dynamic and expanding nature of the analgesics market.
SELECT PLAYERS
Bristol-Myers Squibb Company; Bayer AG; Biological E. Ltd.; Anabolic Laboratories LLC; BioDelivery Sciences International, Inc.; Brawn Laboratories Ltd.; Angelini Holding S.p.A.; AFT Pharmaceuticals Limited; APT Asia Pacific; Church & Dwight (Australia) Pty Ltd.; Alliance Design and Development Group, Inc.; Active Releaf Wellness Inc.; Abiogen Pharma S.p.A.; B-New Limited; Celgene Corporation
SEGMENTS
» Drug Type (Prescription, OTC) » Drug Class (Opioids, NSAIDs, Other Drug Classes) » Route of Administration (Oral, Parenteral, Topical, Transdermal, Rectal)
GEOGRAPHIES
» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Spain » Russia » Rest of Europe » Asia-Pacific » Australia » India » South Korea » Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » UAE » Rest of Middle East » Africa
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Analgesics – Global Key Competitors Percentage Market Share in 2024 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for 146 Players Worldwide in 2024 (E) |
A Prelude to Analgesics |
Analgesics: Perfect Therapeutic Options to Solve Mild to Crippling Pain |
Key Segments |
Opioid Analgesics |
Non-Opioid Analgesics |
Global Analgesics Market to Witness Rapid Growth |
Drugs Indicated for Pain Management |
The US and Europe Represent the Largest Regions, Asia-Pacific to Witness fastest Growth |
Non-Opioids: Fastest Growing Category |
Competition |
Recent Market Activity |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
Growing Aging Population & Increasing Burden of Chronic Diseases Spurs |
Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 |
EXHIBIT: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others |
EXHIBIT: Rising Diabetes Prevalence Presents Opportunity for Cell Surface Markers: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045 |
Growing Incidence of Cancer and the Associated Pain to Drive the Analgesics Market |
EXHIBIT: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 |
Advancements in Design and Delivery of Analgesic Drugs |
Development of Safer Opioids with More Safer Profiles |
Drug Pipeline with Efficacious Drugs |
OTC Analgesics Market to Witness Fastest Growth |
Topical Analgesics Market Holds Significant Share |
Combination Therapies Gain Prominence |
A Few Novel Analgesic Products under Development |
E-commerce Platforms Strengthen Pharmaceutical Distribution in Crisis Period |
Neuropathic Pain Management: Market with High Potential |
Migraine Market: A Core Vertical in CNS Pain Management |
Reyvow, Eli Lilly’s Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market |
Three New Migraine Drugs Obtain FDA Approval |
Eli Lilly’s Emgality Receives FDA Approval |
Increasing Cases of Peripheral Nerve Injuries Drive the Analgesics Market |
4. GLOBAL MARKET PERSPECTIVE |
World Recent Past, Current & Future Analysis for Prescription by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Prescription by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Prescription by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for OTC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for OTC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for OTC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Transdermal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Rectal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Rectal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Rectal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Analgesics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030 |
World Recent Past, Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030 |
WORLD BRANDS |
III. MARKET ANALYSIS |
UNITED STATES |
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E) |
USA Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
USA Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
USA 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
USA Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
USA Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
USA 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
USA Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
USA Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
USA 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
CANADA |
Canada Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Canada Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Canada 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Canada Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Canada Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Canada 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Canada Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Canada Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Canada 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
JAPAN |
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E) |
Japan Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Japan Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Japan 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Japan Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Japan Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Japan 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Japan Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Japan Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Japan 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
CHINA |
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E) |
China Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
China Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
China 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
China Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
China Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
China 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
China Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
China Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
China 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
EUROPE |
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E) |
Europe Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Europe Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Europe 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Europe Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Europe Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Europe 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Europe Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Europe Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Europe 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
Europe Recent Past, Current & Future Analysis for Analgesics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
Europe Historic Review for Analgesics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Europe 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030 |
FRANCE |
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E) |
France Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
France Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
France 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
France Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
France Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
France 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
France Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
France Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
France 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
GERMANY |
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E) |
Germany Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Germany Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Germany 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Germany Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Germany Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Germany 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Germany Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Germany Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Germany 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
ITALY |
Italy Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Italy Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Italy 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Italy Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Italy Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Italy 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Italy Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Italy Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Italy 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
UNITED KINGDOM |
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E) |
UK Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
UK Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
UK 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
UK Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
UK Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
UK 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
UK Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
UK Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
UK 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
SPAIN |
Spain Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Spain Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Spain 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Spain Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Spain Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Spain 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Spain Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Spain Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Spain 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
RUSSIA |
Russia Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Russia Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Russia 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Russia Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Russia Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Russia 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Russia Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Russia Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Russia 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of Europe Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Rest of Europe 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of Europe Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Rest of Europe 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of Europe Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Rest of Europe 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
ASIA-PACIFIC |
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Asia-Pacific 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Asia-Pacific 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Asia-Pacific 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Analgesics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Asia-Pacific 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030 |
AUSTRALIA |
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E) |
Australia Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Australia Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Australia 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Australia Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Australia Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Australia 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Australia Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Australia Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Australia 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
INDIA |
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E) |
India Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
India Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
India 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
India Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
India Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
India 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
India Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
India Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
India 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
SOUTH KOREA |
South Korea Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
South Korea Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
South Korea 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
South Korea Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
South Korea Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
South Korea 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
South Korea Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
South Korea Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
South Korea 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
REST OF ASIA-PACIFIC |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of Asia-Pacific Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Rest of Asia-Pacific 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of Asia-Pacific Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Rest of Asia-Pacific 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of Asia-Pacific Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Rest of Asia-Pacific 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
LATIN AMERICA |
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E) |
Latin America Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Latin America Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Latin America 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Latin America Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Latin America Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Latin America 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Latin America Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Latin America Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Latin America 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
Latin America Recent Past, Current & Future Analysis for Analgesics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
Latin America Historic Review for Analgesics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Latin America 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030 |
ARGENTINA |
Argentina Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Argentina Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Argentina 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Argentina Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Argentina Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Argentina 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Argentina Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Argentina Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Argentina 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
BRAZIL |
Brazil Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Brazil Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Brazil 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Brazil Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Brazil Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Brazil 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Brazil Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Brazil Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Brazil 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
MEXICO |
Mexico Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Mexico Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Mexico 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Mexico Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Mexico Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Mexico 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Mexico Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Mexico Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Mexico 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
REST OF LATIN AMERICA |
Rest of Latin America Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of Latin America Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Rest of Latin America 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Rest of Latin America Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of Latin America Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Rest of Latin America 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Rest of Latin America Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of Latin America Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Rest of Latin America 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
MIDDLE EAST |
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E) |
Middle East Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Middle East Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Middle East 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Middle East Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Middle East Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Middle East 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Middle East Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Middle East Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Middle East 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
Middle East Recent Past, Current & Future Analysis for Analgesics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
Middle East Historic Review for Analgesics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Middle East 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030 |
IRAN |
Iran Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Iran Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Iran 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Iran Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Iran Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Iran 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Iran Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Iran Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Iran 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
ISRAEL |
Israel Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Israel Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Israel 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Israel Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Israel Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Israel 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Israel Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Israel Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Israel 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
SAUDI ARABIA |
Saudi Arabia Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Saudi Arabia Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Saudi Arabia 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Saudi Arabia Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Saudi Arabia Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Saudi Arabia 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Saudi Arabia Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Saudi Arabia Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Saudi Arabia 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
UNITED ARAB EMIRATES |
UAE Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
UAE Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
UAE 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
UAE Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
UAE Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
UAE 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
UAE Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
UAE Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
UAE 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
REST OF MIDDLE EAST |
Rest of Middle East Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of Middle East Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Rest of Middle East 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Rest of Middle East Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of Middle East Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Rest of Middle East 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Rest of Middle East Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of Middle East Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Rest of Middle East 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
AFRICA |
Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E) |
Africa Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Africa Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Africa 16-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2014, 2024 & 2030 |
Africa Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Africa Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Africa 16-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2014, 2024 & 2030 |
Africa Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Africa Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR |
Africa 16-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2014, 2024 & 2030 |
IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com
DIFFERENTIATORS
Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .
What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).
WHAT SETS US APART
FULL STACK DATA ACCESS
- Primary Research Cluster Data
- Influencer Engagement Stats
- Evidence of Primary Research
- List of Companies Engaged
- Hundreds of Pages of Research
- Peer Collaborative Interactions
- Enterprise Data Exchanges
- MarketGlassTM Platform Insider
- Geographic Pricing Dynamics
- Competitive Shares by Country
- Brand Curation & Insights
- Domain Expert Pool
Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.
Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.
Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.
Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.
Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.
Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.
Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.